Yang Liu1, Wenbin Yan2, Yupei Chen3

  • 1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

NPJ digital medicine
|September 1, 2025
PubMed
概括

我们开发了响应适应的个性化风险指数 (RAIRI),以预测助剂化疗 (AC) 在鼻癌 (NPC) 中的益处. RAIRI准确地识别了哪些患者会和不会从AC中受益,从而实现了个性化治疗选择.